Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the neupogen (filgrastim) market size evolved in recent years?

In recent times, the market size for Neupogen (filgrastim) has exhibited robust growth. Projections show an increase from $1,330.69 million in 2024 to $1,404.70 billion in 2025, marking a compound annual growth rate (CAGR) of 5.6%. The growth observed in the historic period can be traced to factors such as rising cases of cancer, increased knowledge of chemotherapy-induced neutropenia, enhancements in healthcare infrastructure, expedited approvals for Neupogen biosimilars, and an uptick in global healthcare expenditure.

What are the predictions for the neupogen (filgrastim) market size in the coming years?

In the coming years, robust growth is anticipated for the neupogen (filgrastim) market, with its size anticipated to reach $1,727.05 million by 2029, growing at a compound annual growth rate (CAGR) of 5.3%. The projected growth during this period is primarily due to factors such as the increasing demand for affordable neutropenia treatments, broader healthcare availability in developing markets, enhanced government backing for biosimilar adoption, greater emphasis on personalized medicine, and an expanding older population. The forecast period is expected to see trends such as escalated investment in research and development for biosimilars, advancements in neutropenia treatment drug delivery systems, increasing collaborations for the commercialization of oncology drugs, heightened attention to patient affordability initiatives, and development of next-generation G-CSF products.

Get your neupogen (filgrastim) market report here!

https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-

What key factors are fueling the growth of the neupogen (filgrastim) market?

The expected surge in the incidence of numerous diseases will likely spur the growth of the neupogen (filgrastim) market. A disease is a disorder in the body’s structure or function that results in specific symptoms and impacts particular areas, often triggered by genetics, environmental factors, infections, or lifestyle habits. The escalating prevalence of varying diseases is attributed to aspects such as growing older populations, sedentary lifestyles, rising pollution, poor diet, and the global expansion of infectious disease agents. Neupogen (filgrastim), by stimulating neutrophil production, helps manage the issues linked to chemotherapy-induced neutropenia, augmenting the ability of the immune system to fight infections in immunocompromised patients. It plays a key role in lowering hospitalization rates, handling infection hazards, and ensuring continuous cancer treatment schedules for patients receiving intensive treatments. In April 2024, according to charity Allergy UK, over 21 million individuals in the UK reported suffering from allergies, the most frequently reported chronic health condition in 2022, with forecasts suggesting that by 2026, half the population of Europe would have at least one allergy. Moreover, as per Macmillan Cancer Support in June 2022, 3 million people were living with cancer in 2022 in the UK, anticipated to rise to almost 3.5 million by 2025 and 4 million by 2030. Thus, the rising prevalence of numerous diseases is propelling the growth of the neupogen (filgrastim) market. Government-supported healthcare research and development initiatives are anticipated to drive the growth of the neupogen (filgrastim) market. These initiatives are specific measures undertaken by government bodies at various levels (local, regional, national or international) to tackle particular issues, reach certain objectives or bring about positive societal changes. Numerous government bodies are launching various healthcare initiatives that cover a range of aspects including neupogen (filgrastim). In 2022, for instance, according to the Department of Health and Social Care, the UK government announced funding of £260 million (US $270.65 million) to spur healthcare research and manufacturing. It was pledged by BEIS and DHSC to support NHS-led research into diagnostics and treatment via novel, privacy-preserving platforms and clinical research services, and £60 million (US $63.60 million) was allocated to expand life sciences manufacturing in the UK. Consequently, governmental initiatives for healthcare research and development stimulate the neupogen (filgrastim) market.

How is the global neupogen (filgrastim) market divided into key segments?

The neupogen (filgrastim)market covered in this report is segmented –

1) By Drug Type: Biologic; Biosimilar

2) By Indication: Chemotherapy Induced Neutropenia; Chronic Neutropenia; Others

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp

Who are the key firms paving the way for growth in the neupogen (filgrastim) market?

Major companies operating in the neupogen (filgrastim) market include Amgen Inc.

Which trends are expected to transform the neupogen (filgrastim) market?

A prominent trend emerging in the Neupogen (filgrastim) market revolves around the production of innovative filgrastim biosimilar products serving as an affordable and reachable substitute for the treatment of chemotherapy-induced neutropenia. Such biosimilar solutions mimic the original filgrastim (Neupogen) in terms of safety, efficacy, and structure with their primary function being the stimulation of neutrophil production in chemotherapy patients to prevent neutropenia. An example of this came about in November 2022, when US-based pharmaceutical firm Amneal Pharmaceuticals and biopharmaceutical company Kashiv Biosciences introduced Releuko (filgrastim-ayow) – a biosimilar to Neupogen (filgrastim) in the US market. Releuko comes in various intravenous and subcutaneous single-dose vial and prefilled syringe formats, offering dosage flexibility to healthcare professionals. It is crucial in promoting a budget-friendly treatment solution for chemotherapy-induced neutropenia, increasing the accessibility of vital oncology care and responding to the heightened market demand for biosimilars.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19910

What regions are contributing significantly to the growth of the neupogen (filgrastim) market?

North America was the largest region in the neupogen (filgrastim) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Filgrastim Biosimilars Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Pegfilgrastim Biosimilars Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Chronic Lymphocytic Leukemia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lymphocytic-leukemia-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: